$39.31 -0.21 (-0.53%)
2/10/2012 4:00 PM

Eli Lilly & Co. (NYSE:LLY)

CAPS Rating: 4 out of 5

The Company discovers, develops, manufactures and sells products in one of its business segment of pharmaceutical products to prevent and treat human diseases.

Results 1 - 20 of 201 : 1 2 3 4 5 6 7 8 9 10 Next »

Recs

0
Member Avatar nveagle (< 20) Submitted: 1/31/2012 12:03:54 PM : Outperform Start Price: $39.51 LLY Score: -3.15

Nice steady dividend.

Recs

0
Member Avatar slih (< 20) Submitted: 1/26/2012 12:58:31 AM : Outperform Start Price: $39.91 LLY Score: -2.41

veternary products; retained corporate brainpower

Recs

0
Member Avatar fooluser17 (89.00) Submitted: 1/19/2012 2:04:19 PM : Outperform Start Price: $40.17 LLY Score: -4.32

Dividend rockstar, most numbers are good. Probably make this one 1%.

Recs

0
Member Avatar jesseangels (< 20) Submitted: 1/13/2012 7:41:59 PM : Outperform Start Price: $40.16 LLY Score: -5.41

Undervalued. Target ~50$.

Recs

0
Member Avatar guinness4life (34.55) Submitted: 12/21/2011 6:21:56 PM : Outperform Start Price: $41.77 LLY Score: -13.70

Long this. Gorgeous value stock with great dividend. I got in a few months ago. Get in the next time a drug misses approval.

Recs

0
Member Avatar dswinters (94.33) Submitted: 12/14/2011 2:02:31 PM : Outperform Start Price: $40.29 LLY Score: -12.52

Solid Dividend and several divisions of the company are putting off free cash flow to make this a safe, longer term pick.

Recs

0
Member Avatar GMoneyCaps (97.95) Submitted: 12/13/2011 8:08:31 PM : Outperform Start Price: $39.61 LLY Score: -10.39

12/13

Recs

0
Member Avatar GETRICHSLOW2 (87.27) Submitted: 12/12/2011 10:16:26 PM : Outperform Start Price: $39.05 LLY Score: -6.94

Falling off the patent cliff but the metrics look outstanding. A great time to buy in. Company has been around since 1901. I doubt they will go under just because of a few patent expirations. Currently yielding 5%. p/e=8.5, payout ratio=43%, beta= 0.67.

Buy Buy Buy!

Recs

0
Member Avatar Divlover (30.50) Submitted: 12/8/2011 4:09:44 PM : Outperform Start Price: $38.94 LLY Score: -7.46

Possible Alzhiemer drug in the works and a nice dividend.

Recs

0
Member Avatar SearchS (42.44) Submitted: 12/6/2011 9:27:59 PM : Outperform Start Price: $39.27 LLY Score: -6.67

Promising drugs in the pipeline...

Recs

0
Member Avatar birdup (32.67) Submitted: 12/6/2011 7:06:47 PM : Outperform Start Price: $39.27 LLY Score: -6.67

Cramer

Recs

0
Member Avatar sshbeeb (< 20) Submitted: 10/12/2011 1:19:39 PM : Outperform Start Price: $36.26 LLY Score: -1.98

They are owners of several frequently used medicines for common chronic conditions.

Recs

0
Member Avatar Ipad (< 20) Submitted: 9/22/2011 11:30:14 PM : Outperform Start Price: $35.93 LLY Score: -9.91

fundamentals look very goog

Recs

0
Member Avatar giannelli5 (< 20) Submitted: 8/11/2011 12:59:01 PM : Outperform Start Price: $34.50 LLY Score: -1.58

Good dividend; bought near low

Recs

0
Member Avatar Fabuloso (35.91) Submitted: 8/2/2011 11:38:52 AM : Outperform Start Price: $36.44 LLY Score: +2.35

A Great Dividend stock with Low PE. LLY will take you through the never endless recession with a decent return over your investment. On the other hand, the expiring patents and the government will hit the stock. But if it’s not LLY, where will you go, Treasuries ???

Recs

0
Member Avatar jbuttvt (88.43) Submitted: 7/21/2011 9:06:45 PM : Outperform Start Price: $38.15 LLY Score: +3.17

cheap, dividend, good investment returns

Recs

0
Member Avatar d0w0kelley (< 20) Submitted: 7/10/2011 12:52:02 AM : Outperform Start Price: $36.41 LLY Score: +6.77

Large cap stock, price above 14-day moving average

Recs

0
Member Avatar gh0stith3machin3 (< 20) Submitted: 7/2/2011 1:07:32 AM : Outperform Start Price: $36.61 LLY Score: +6.84

Good dividend growth, good balance sheet.

Recs

0
Member Avatar DSmod (61.03) Submitted: 6/29/2011 12:58:52 PM : Outperform Start Price: $36.22 LLY Score: +5.77

Historically low price for a solid company with a good dividend to tide you over while you wait for better times. I also like that because it is a drug developer, LLY's success is not necessarily bound to the economy.

Recs

0
Member Avatar ipsiety (26.59) Submitted: 6/27/2011 8:33:51 AM : Outperform Start Price: $35.88 LLY Score: +3.67

Low PE, look at ROE of 25.6%.

Featured Broker Partners


Advertisement